Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

Thumbnail for Real-World Treatment Patterns, Chimeric Antigen Receptor (CAR) T Cell Therapy Referral Barriers, and Time-to-Next Treatment (TTNT) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) Who Experienced Progression ≤24 Months of First-Line Che

CT - 341

Real-World Treatment Patterns, Chimeric Antigen Receptor (CAR) T Cell Therapy Referral Barriers, and Time-to-Next Treatment (TTNT) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) Who Experienced Progression ≤24 Months of First-Line Che

Sairah Ahmed

Poster Presenter: Sairah Ahmed

Thumbnail for Ropeginterferon Alfa-2b in Polycythemia Vera: A PRISMA-Compliant Systematic Review and Meta-Analysis

MPN - 345

Ropeginterferon Alfa-2b in Polycythemia Vera: A PRISMA-Compliant Systematic Review and Meta-Analysis

Allah Dad

Poster Presenter: Allah Dad

Previous 1...24 25 26 27 28 29 30...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-Cel) and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma

ABCL - 346

Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-Cel) and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma

Sagar Patel

Poster Presenter: Sagar Patel

Thumbnail for MYELOVAC: A Phase 1 Trial of a Personalized Peptide-Based Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients With Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy an

AML - 347

MYELOVAC: A Phase 1 Trial of a Personalized Peptide-Based Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients With Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy an

Nikolaos Spyrou

Poster Presenter: Nikolaos Spyrou

$Thumbnail for Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk$

MM - 349

Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk

Kaci Ernst

Poster Presenter: Kaci Ernst

Thumbnail for Suicide Mortality Among Hematological Malignancy Survivors: A Population-Based SEER-CDC analysis

AML - 350

Suicide Mortality Among Hematological Malignancy Survivors: A Population-Based SEER-CDC analysis

Vidushi Reddy Gillela

Poster Presenter: Vidushi Reddy Gillela

Thumbnail for Extraosseous Plasmacytoma: Real-World Outcomes of a Rare Plasma Cell Neoplasm using the SEER Database

MM - 351

Extraosseous Plasmacytoma: Real-World Outcomes of a Rare Plasma Cell Neoplasm using the SEER Database

Vidushi Reddy Gillela

Poster Presenter: Vidushi Reddy Gillela

Thumbnail for ALK Status, Clinical Features, and Outcomes in Anaplastic Large Cell Lymphoma: Experience from a National Reference Center in Hispanic Population

TCL - 352

ALK Status, Clinical Features, and Outcomes in Anaplastic Large Cell Lymphoma: Experience from a National Reference Center in Hispanic Population

Amairani Carpintero Diaz

Poster Presenter: Amairani Carpintero Diaz

Thumbnail for BGB-16673, a potent BTK degrader in human blood and cancer cell lines, shows high selectivity in both proteomics and kinome panel analysis

CLL - 353

BGB-16673, a potent BTK degrader in human blood and cancer cell lines, shows high selectivity in both proteomics and kinome panel analysis

Haitao Wang

Poster Presenter: Haitao Wang

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors